ASX Announcements

New milestone as LCT and OptiCellAI advance AI for NTCELL's manufacture, as part of LCT's third clinical trial of NTCELL in Parkinson's disease.

Living Cell Technologies has received a notice pursuant to Section 249D of the Corporations Act 2001.

Notice of initial substantial holder for Living Cell Technologies (ASX:LCT).

Change of Director's Interest Notice for LCT Director Robert Willcocks, who has acquired an additional 500,000 ordinary shares in LCT.

Living Cell Technologies provides notification of the issue of unlisted options under an employee incentive scheme.